Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE) January 31, 2022 -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the“Company”) today announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials